Search Within

Wassim Abida

Formats
  1. Meeting Abstract (75)
  2. Journal Article (69)
  3. Editorial (4)
  4. Research Letter (2)
  5. Review (2)
  6. Correspondence (1)
  7. Guidelines (1)
Groups
  1. Department of Medicine (154)
  2. Genitourinary Oncology Service (154)
  3. Solid Tumor Oncology Division (154)
  4. GSK Faculty (71)
  5. Human Oncology and Pathogenesis Program (67)
  6. Sloan Kettering Institute Postdocs (57)

More Groups

People
  1. Howard Scher (68)
  2. Michael Morris (38)
  3. David Solit (36)
  4. Nikolaus Schultz (32)
  5. Anuradha Gopalan (31)
  6. Dana Rathkopf (31)

More People

Years
  1. 2025 (4)
  2. 2024 (10)
  3. 2023 (14)
  4. 2022 (15)
  5. 2021 (19)
  6. 2020 (27)

More Years

Publications
  1. Journal of Clinical Oncology (40)
  2. Clinical Cancer Research (15)
  3. Annals of Oncology (13)
  4. Cancer Research (13)
  5. European Urology (8)
  6. JCO Precision Oncology (4)

More Publications

Publishers
  1. American Society of Clinical Oncology (44)
  2. American Association for Cancer Research (31)
  3. Nature Publishing Group (15)
  4. Oxford University Press (13)
  5. Elsevier Science, Inc. (10)
  6. Nature Research (5)

More Publishers

Results (154)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Guidelines for management of treatment-emergent adverse events during rucaparib treatment of patients with metastatic castration-resistant prostate cancer
    Guidelines

    Labadie, B. W.; Morris, D. S.; Bryce, A. H.; Given, R.; Zhang, J.; Abida, W.; Chowdhury, S.; Patnaik, A.
    Cancer Management and Research (2022)

    Fulltext@MSK | Save
  • Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients
    Journal Article

    Nguyen, B.; Fong, C.; Luthra, A.; Smith, S. A.; DiNatale, R. G.; Nandakumar, S.; Walch, H.; Chatila, W. K.; Madupuri, R.; Kundra, R.; more...
    Cell (2022)

    Fulltext@MSK | Save
  • Differences in prostate cancer genomes by self-reported race: Contributions of genetic ancestry, modifiable cancer risk factors, and clinical factors
    Journal Article

    Stopsack, K. H.; Nandakumar, S.; Arora, K.; Nguyen, B.; Vasselman, S. E.; Nweji, B.; McBride, S. M.; Morris, M. J.; Rathkopf, D. E.; Slovin, S. F.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Response to rucaparib in BRCA-mutant metastatic castration-resistant prostate cancer identified by genomic testing in the TRITON2 study
    Journal Article

    Loehr, A.; Patnaik, A.; Campbell, D.; Shapiro, J.; Bryce, A. H.; McDermott, R.; Sautois, B.; Vogelzang, N. J.; Bambury, R. M.; Voog, E.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • Interim results of AASUR: A single arm, multi-center phase 2 trial of apalutamide (A) + abiraterone acetate + prednisone (AA plus P) + leuprolide with stereotactic ultra-hypofractionated radiation (UHRT) in very high risk (VHR), node negative (N0) prostate cancer (PCa)
    Meeting Abstract

    McBride, S. M.; Spratt, D. E.; Kollmeier, M.; Abida, W.; Xiao, H.; Slovin, S. F.; Paller, C. J.; Deville, C.; Den, R. B.; Hearn, J. W. D.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Characterization of findings on prostate cancer tumor sequencing that should prompt consideration for germline testing
    Meeting Abstract

    Truong, H.; Breen, K.; Kemel, Y.; Lenis, A. T.; Reisz, P.; Benfante, N.; Ehdaie, B.; Touijer, K. A.; Laudone, V. P.; Scardino, P. T.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Tazemetostat in combination with a PARP Inhibitor or checkpoint inhibitor in patients (Pts) with solid tumors
    Meeting Abstract

    Rudin, C. M.; Abida, W.; Spira, A.; Chadha, R.; Yang, J.; Powers, D.; Coleman, R.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Safety of tazemetostat (TAZ) in combination with abiraterone/prednisone (A/P) or enzalutamide (E) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Abida, W.; Iannotti, N.; Kocabas Argon, E.; Appleman, L.; Michaud, N.; Rajarethinam, A.; Adib, D.; Saltzstein, D. R.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • A phase Ib study of enzalutamide (Enza) plus CC-115 in men with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Zhao, J. L.; Antonarakis, S.; Cheng, H.; George, D. J.; Aggarwal, R. R.; Abida, W.; Decker, B.; Smart-Curley, T.; Schonhoft, J.; Anderson, A.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Therapeutic implications of germline testing in patients with advanced cancers
    Journal Article

    Stadler, Z. K.; Maio, A.; Chakravarty, D.; Kemel, Y.; Sheehan, M.; Salo-Mullen, E.; Tkachuk, K.; Fong, C. J.; Nguyen, B.; Erakky, A.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save